John Quisel

Stories

Disc Medicine's rejected sun-sensitivity drug clears Phase 3, reopening FDA path

Preparing bitopertin's NDA resubmission by the end of 2026

People with erythropoietic protoporphyria feel stabbing pain in strong light, and no oral drug is approved to help them. Disc Medicine's bitopertin passed a 183-patient Phase 3 trial called APOLLO, the company said on Oct. 19, 2026, reopening a path to the FDA after a rejection in February.

Updated Oct 25

Notable Quotes

"Today represents a potential breakthrough in the science and treatment of EPP." — John Quisel, Oct 19, 2026

from Disc Medicine's rejected sun-sensitivity drug clears Phase 3, reopening FDA path · Updated Oct 25

"They have a lot of priorities, so we will certainly ask, and we'll see what we get." — John Quisel, on asking the FDA for a faster review than six months, Oct. 19, 2026

from Disc Medicine's rejected sun-sensitivity drug clears Phase 3, reopening FDA path · Updated Oct 25

"These results mark a significant scientific advancement in EPP … I expect these results will permanently change the focus of drug development in this field." — John Quisel, on the Oct. 19, 2026 conference call

from Disc Medicine's rejected sun-sensitivity drug clears Phase 3, reopening FDA path · Updated Oct 25